Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA

2:21
 
Share
 

Manage episode 525064183 series 3665342
Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, review new research on integrating unstructured health data to scale eSource-enabled trials, and cover Novo Nordisk’s NDA submission for its fixed-dose amylin–GLP-1 obesity therapy, CagriSema.
  continue reading

118 episodes

Artwork
iconShare
 
Manage episode 525064183 series 3665342
Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, review new research on integrating unstructured health data to scale eSource-enabled trials, and cover Novo Nordisk’s NDA submission for its fixed-dose amylin–GLP-1 obesity therapy, CagriSema.
  continue reading

118 episodes

所有剧集

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play